Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pranlukast - Ono Pharmaceutical

Drug Profile

Pranlukast - Ono Pharmaceutical

Alternative Names: Azlaire; Dolukast hydrate; ONO 1078; ONO RS 411; Onon; Onon Capsule; Onon Dry Syrup; RS 411; SB 205312; Ultair

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ono Pharmaceutical
  • Developer Merck & Co; Ono Pharmaceutical
  • Class Antiallergics; Antiasthmatics; Chromones; Small molecules
  • Mechanism of Action Leukotriene C4 receptor antagonists; Leukotriene D4 receptor antagonists; Leukotriene E4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Allergic rhinitis; Asthma
  • Discontinued Chronic obstructive pulmonary disease; Inflammatory bowel diseases; Sinusitis

Most Recent Events

  • 22 Dec 2011 Registered as dry syrup formulation for Allergic rhinitis (in children) in Japan (PO)
  • 30 Apr 2011 Preregistration as dry syrup formulation for Allergic rhinitis (in children) in Japan (PO)
  • 17 Mar 2009 Pharmacokinetics data from a phase I trial in patients with Asthma presented at the 65th Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2009)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top